Effect of combined photodynamic therapy and photobiomodulation therapy in the management of recurrent herpes labialis

Effect of combined photodynamic therapy and photobiomodulation therapy in the management of recurrent herpes labialis: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10142572

Enrollment

Registered

2025-01-20

Start date

2024-06-02

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent herpes labialis Infections and Infestations

Interventions

Patients referred to the Department of Oral Medicine were evaluated for eligibility. From a total of 73 patients, 60 were randomly assigned into three groups (n = 20): • Group 1 (control): 5% Acyclovi

Eligibility

Sex/Gender

All

Age

19 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Healthy participants. 2. Participants older than 18 years. 3. Participants had a history of RHL. 4. Participants had a current active vesicular infection.

Exclusion criteria

Exclusion criteria: 1. Smokers. 2. Pregnant and breastfeeding women. 3. Diabetic patients. 4. Immunocompromised patients. 5. Participants were allergic to the agents used. 6. Patients had skin lesions that affected the course of healing or interfered with the current study. 7. Patients taking antiviral medications over the four weeks before treatment. 8. Patients taking anti-inflammatory drugs or antibiotics over the two weeks before treatment.

Design outcomes

Primary

Measure	Time frame
1. Pain intensity Pain intensity was measured using a visual analog scale (VAS), at the following time points: •At the baseline (t0). •After applying the laser in the first session (t1). •Before applying the laser in the second session, after 48 hours (t2). •After applying the laser in the second session (t3). •After 7 days of follow-up (t4). VAS scores were as follows: •0 = No pain. •1–3 = Mild pain. •4–6 = Moderate pain. •7–9 = Severe pain. •10 = Worst pain possible. 2. Lesion healing The point of healing was considered to be the spontaneous shedding of the crust from the lesion. Patients were followed up, and the day the crust fell off spontaneously was recorded.	—

Measure

Time frame

1. Pain intensity Pain intensity was measured using a visual analog scale (VAS), at the following time points: •At the baseline (t0). •After applying the laser in the first session (t1). •Before applying the laser in the second session, after 48 hours (t2). •After applying the laser in the second session (t3). •After 7 days of follow-up (t4). VAS scores were as follows: •0 = No pain. •1–3 = Mild pain. •4–6 = Moderate pain. •7–9 = Severe pain. •10 = Worst pain possible. 2. Lesion healing The point of healing was considered to be the spontaneous shedding of the crust from the lesion. Patients were followed up, and the day the crust fell off spontaneously was recorded.

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Syria

Contacts

Public ContactMawia Karkoutly

mawia95.karkoutly@damascusuniversity.edu.sy+963 (0)992 647 528

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 19, 2026